Review
Copyright ©The Author(s) 2023.
World J Biol Chem. Mar 27, 2023; 14(2): 13-27
Published online Mar 27, 2023. doi: 10.4331/wjbc.v14.i2.13
Table 1 Differences in early-onset colorectal cancer and later-onset colorectal cancer DNA mutations
Gene
Prevalence in EOCRC vs LOCRC1
Role in cancer
APCDecreased[33,34,44,45]Blocks β-catenin, tumor suppressor
CTNNB1Increased[33,34]β-catenin, potentiates Wnt signaling, proliferation, and stemness
RNF43Increased[43]/NS[33]E3 ligase, negative regulator of Wnt signaling
BRCA2Increased[54]Double stranded DNA repair, tumor suppressor
PHLPP1Increased[54]Promotes apoptosis, inhibits AKT
TOPORSIncreased[54]Regulates TP53 stability, likely tumor suppressor
ATRIncreased[54]PI3/PI4 kinase, activates checkpoint proteins
MYCBP2Increased[54]MYC binding protein, activates MYC
FBXW7Increased[44,54]Ubiquitin ligase component, ubiquitinates MYC
POLEIncreased[44,54]DNA polymerase E subunit, proofreading and DNA repair
BRAFDecreased[34,38,57]/increased[43]Proto-oncogene, activates MAPK signaling
TP53Decreased[38,52] Cell cycle inhibitor, tumor suppressor
NOMO1Increased[53,126]Inhibits nodal signaling. Deletion increases CRC cell migration
MYC Increased[50,51]/NS[43,47]Proto-oncogenic transcription factor, promotes proliferation and stemness
DNMT3BDecreased[43]De-novo DNA methyltransferase
METDecreased[43]Proto-oncogene, promotes cell growth and survival
PTENIncreased[57]Tumor suppressor, negatively regulates AKT signaling
KRASDecreased[99,120]Proto-oncogene, activates oncogenic signaling pathways
Table 2 Differentially expressed transcripts in early-onset colorectal cancer
Gene(s)
Description
MYCProto-oncogenic transcription factor, increased in EOCRC tumors vs normal samples[50,69]
ASCL2Transcription factor that promotes intestinal stem cells, increased expression in younger CRC[69]
ALDH1A1Protein involved in cancer cell stemness, expressed higher in EOCRC tumors[88]
PEG10Promotes proliferation and invasion, increased in EOCRC tumor vs normal and EOCRC vs LOCRC[70]
miR-143, miR-125bmiRNAs, under-expressed in EOCRC tumor vs normal[76]
miR-106amiRNA, overexpressed in EOCRC tumor vs normal[76]
hsa-miR-4304, hsa-miR-513a-5p, hsa-miR-628-3p, hsa-miR-194-3p, hsa-miR-193a-5p, hsa-miR-210, and hsa-miR-4453miRNAs uniquely overexpressed in EOCRC compared with LOCRC and normal tissues[75]
SAA1, C7, CFDImmune genes differentially expressed in EOCRC vs LOCRC tumors[73]
NRF2Protein involved in oxidative stress and inflammation, expressed higher in EOCRC vs LOCRC[74]
Table 3 Early-onset colorectal cancer biomarkers
Name
Type
Description
mSEPT9Methylation, DNABlood-based biomarker used in Epi proColon® or both EOCRC and LOCRC[112]
miR-193a-5p, miR-210, miR-513a-5p, miR-628-3pmiRNAsmiRNA in serum, panel works for both EOCRC and LOCRC[75]
Sat2, LINE-1, AluMethylation, DNADNA repetitive elements with increased methylation in EOCRC in white blood cells[62]
miR-31-5p, DMDmiRNA, mRNATranscripts uniquely overexpressed in sporadic EOCRC tumor vs normal and not in LOCRC. miR-3105p targets DMD and it's downregulated in EOCRC[116]
MYCmRNA Transcription factor with increased tumor expression in EOCRCs may subset patients into distinct groups[50,69]